ArticlePharmacogenomics2020
Assessing COVID-19 susceptibility through analysis of the genetic and epigenetic diversity of ACE2-mediated SARS-CoV-2 entry.
Article in Pharmacogenomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- The COVID-19 legacy: consequences for the human DNA methylome and therapeutic perspectives.GeroScience · 2025Review
- Involvement of epigenetics in affecting host immunity during SARS-CoV-2 infection.Biochimica et biophysica acta. Molecular basis of disease · 2023Review
- ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra- and inter-species host-switching of the virus.Frontiers in microbiology · 2023Article
- Premenopausal and postmenopausal women during the COVID-19 pandemic.Przeglad menopauzalny = Menopause review · 2022Review
- Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.Journal of clinical medicine · 2022Review
- Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic?Reviews in endocrine & metabolic disorders · 2022Review
- A New Perspective of COVID-19 Infection: An Epigenetics Point of View.Global medical genetics · 2022Review
- COVID-19 Vaccine: Between Myth and Truth.Vaccines · 2022Review
- Evolutionary Traits and Genomic Surveillance of SARS-CoV-2 in South America.Global health, epidemiology and genomics · 2022Review
- The severity of SARS-CoV-2 infection is dictated by host factors? Epigenetic perspectives.Current research in microbial sciences · 2021Review
- Regulation of m6A Methylation as a New Therapeutic Option against COVID-19.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Gender and genetic factors impacting COVID-19 severity.Journal of family medicine and primary care · 2021Review
- Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.International journal of molecular sciences · 2021Review
- Host Sex Steroids Interact With Virus Infection: New Insights Into Sex Disparity in Infectious Diseases.Frontiers in microbiology · 2021Review
- Systematic review on role of structure based drug design (SBDD) in the identification of anti-viral leads against SARS-Cov-2.Current research in pharmacology and drug discovery · 2021Review
- The Looming Effects of Estrogen in Covid-19: A Rocky Rollout.Frontiers in nutrition · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There is considerable variation in disease course among individuals infected with SARS-CoV-2. Many of them do not exhibit any symptoms, while some others proceed to develop COVID-19; however, severity of COVID-19 symptoms greatly differs among individuals. Focusing on the early events related to SARS-CoV-2 entry to cells through the ACE2 pathway, we describe how variability in (epi)genetic factors can conceivably explain variability in disease course. We specifically focus on variations in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.